STOCKSCREENR

MNPR

NASDAQ

Monopar Therapeutics Inc.

$60.27-1.26(-2.05%)Mkt Cap: $402.76M

Key Stats

Market Cap

$402.76M

P/E Ratio

-15.22

EPS

$-3.96

Dividend Yield

0.00%

52-Week Range

$26.05 — $105.00

Volume

318.77K

Avg Volume

277.45K

Beta

1.67

Valuation

P/E (TTM)

-15.22

Forward P/E

PEG Ratio

1.01

P/S (TTM)

0.00

P/B (TTM)

2.87

P/FCF

EV/EBITDA

EV/Sales

Financial Health

ROE (TTM)

-0.26%

ROA (TTM)

-0.13%

ROIC

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

Debt/Equity

0.00

Current Ratio

56.10

Growth

EPS Growth (YoY)

Revenue Growth (YoY)

EPS Growth (3Y)

-0.39%

EPS Growth (5Y)

-0.38%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-3.23

EPS Est (Next Year)

$-3.83

Dividends

Dividend Yield

Annual Dividend

Payout Ratio

Frequency

Ex-Dividend Date

Cash/Share

$20.17

Analyst Consensus

Price Target Range

$85.00$110.00$125.00
LowMedianHigh

Consensus Target: $108.38(79.8% upside)

Ownership

Institutional %

Inst. Net Change

Insider Net Shares (90d)

-3621

Outstanding Shares

6.68M

Float

4.54M

Free Float %

68.01%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2019-12-19

Employees

14

CEO

Chandler D. Robinson

Index Membership

Website

https://www.monopartx.com

Monopar Therapeutics Inc. (MNPR) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $402.76M, a P/E ratio of -15.22, MNPR is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare MNPR against other stocks using dozens of fundamental and technical filters.

Similar Stocks

Frequently Asked Questions

What is Monopar Therapeutics Inc.'s P/E ratio?

Monopar Therapeutics Inc. (MNPR) has a trailing twelve-month (TTM) P/E ratio of -15.22. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Monopar Therapeutics Inc. pay a dividend?

No, Monopar Therapeutics Inc. (MNPR) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Monopar Therapeutics Inc.'s market cap?

Monopar Therapeutics Inc. (MNPR) has a market capitalization of $402.76 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.